An investigation of 125| seed permanent implantation for recurrent carcinoma in the head and neck after surgery and external beam radiotherapy

被引:36
作者
Zhu, Lihong [1 ]
Jiang, Yuliang [1 ]
Wang, Junjie [1 ]
Ran, Weiqiang [2 ]
Yuan, Huishu [3 ]
Liu, Chen [3 ]
Qu, Ang [1 ]
Yang, Ruijie [1 ]
机构
[1] Peking Univ, Dept Radiat Oncol, Hosp 3, Beijing 100191, Peoples R China
[2] Peking Univ, Dept Ultrasound, Hosp 3, Beijing 100191, Peoples R China
[3] Peking Univ, Dept Radiol, Hosp 3, Beijing 100191, Peoples R China
关键词
(125)vertical bar seed; Head and neck carcinoma; Surgery; External beam radiotherapy; SQUAMOUS-CELL CANCER; RADIATION-THERAPY; I125; IMPLANTS; REIRRADIATION; TONGUE; 5-FLUOROURACIL; BRACHYTHERAPY; IRRADIATION; EXPERIENCE; ADJUVANT;
D O I
10.1186/1477-7819-11-60
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: A preliminary assessment was conducted of the feasibility, efficacy, and morbidity of (125)vertical bar seed implantation for recurrent head and neck carcinoma after surgery and external beam radiotherapy. Methods: Nineteen patients with recurrent head and neck carcinomas underwent (125)vertical bar seed implantation under ultrasound or computed tomography guidance. The actuarial D90 of (125)vertical bar seed implantation ranged from 90 to 160 Gy (median, 131 Gy). The follow-up period ranged from 3 to 44 months (median, 11 months). Results: The median local control was 24 months (95% confidence interval, 10.2 to 37.8). The one- year, two-year and three-year local controls were 73.3%, 27.5% and 27.5%, respectively, whereas the one-year, two-year and three-year survival rates were 53.0%, 18.2% and 18.2%, respectively, and the median survival was 13 months (95% confidence interval, 6.6 to 19.4). A total of 26.3% of patients (5/19) died of local recurrence and 21.1% of patients (4/19) died of metastases. One suffered from a grade 1 skin reaction. Conclusions: (125)vertical bar seed implantation is feasible and safe as a salvage treatment for patients with recurrent head and neck cancers. The high local control results and low morbidity merits further investigation.
引用
收藏
页数:7
相关论文
共 46 条
[1]  
Ash D, 1986, ACTA RADIOL, V16, P369
[2]  
Ashamalla H, 1983, RADIOLOGY S, V189, P213
[3]  
Ashamalla Hani, 2002, Brachytherapy, V1, P161, DOI 10.1016/S1538-4721(02)00054-5
[4]   TOXICITY CRITERIA OF THE RADIATION-THERAPY ONCOLOGY GROUP (RTOG) AND THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC) [J].
COX, JD ;
STETZ, J ;
PAJAK, TF .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (05) :1341-1346
[5]  
DECROIX Y, 1981, CANCER-AM CANCER SOC, V47, P496, DOI 10.1002/1097-0142(19810201)47:3<496::AID-CNCR2820470312>3.0.CO
[6]  
2-Q
[7]  
EMAMI B, 1987, LARYNGOSCOPE, V97, P85
[8]  
EMAMI B, 1983, LARYNGOSCOPE, V93, P1345
[9]  
FEE WE, 1983, ARCH OTOLARYNGOL, V109, P727
[10]  
Geiger Matthias, 2002, Brachytherapy, V1, P149, DOI 10.1016/S1538-4721(02)00056-9